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Background: Influenza virus poses serious threats to human health, especially human infection with avian influenza
virus. Laggera pterodonta (DC.) Benth is a medicinal plant that is widely used in Traditional Chinese Medicine,
especially in Yunnan province, and has been used to treat influenza, pharyngolaryngitis, and bronchitis. However,
the compound(s) responsible for the activity and their mechanisms of action against the influenza virus remain to
be elucidated.
Methods: L. pterodonta extract was fractionated, and the active fraction was identified as Fraction 14 (Fr 14).
Fr 14 was further analysed and characterized by ultra-high-performance liquid chromatography hyphenated with
quadrupole-time of flight mass spectrometry (UHPLC/Q-TOF-MS). The inhibitory effect against influenza virus was
evaluated using a cytotoxicity assay. Then, cytokines and chemokines were detected by qRT-PCR and a bio-plex
assay. Signalling pathways that inhibited the influenza virus were identified using a western blotting assay.
Results: The active fr 14 showed a wide spectrum of anti-influenza virus activity. The pharmacological mechanisms
showed that Fr 14 acts on the early stage of virus replication (0–6 h). It inhibited the p38/MAPK pathway and then
inhibited the NF-κB pathway and COX-2. Fr 14 also prevented the increased expression of cytokines and
chemokines.
Conclusion: This study demonstrated the preliminary mechanisms of fr 14 against the influenza virus. Fr 14
possessed antiviral and anti-inflammatory effects. L. pterodonta can be used to develop innovative antiviral
drugs, and further studies will be performed to illustrate the detailed mechanisms.
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Influenza viruses belong to the Orthomyxoviridae family
and include types A, B, and C. Influenza A viruses have
a wide spectrum of hosts and cause human respiratory
infection, leading to severe annual morbidity and mortality.
When the viruses undergo adaptive evolution, they can
produce cross-species transmission between human and* Correspondence: xinhuaw@gzhmu.edu.cn
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(http://creativecommons.org/publicdomain/zeavian [1]. Recently, newly emerged influenza, such as
H7N9, H10N8, and H5N6, have caused a severe threat to
human health, especially the H7N9 virus, which has high
rates of severe illness and death in patients [2].
To fight against these pathogens, some antiviral drugs
have been developed and used in clinical practice, in-
cluding oseltamivir, peramivir, zanamivir, amantadine,
and rimantadine. Adamantine-derived drugs are not
recommended due to drug resistance. All of the above
antiviral drugs are resistant to influenza virus and are
restricted to use in the clinic [3, 4].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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drugs is urgently needed. Laggera pterodonta (DC.) Benth
is a medicinal plant that is widely used in Traditional
Chinese Medicine, especially in Yunnan province, and is
used to treat influenza, pharyngolaryngitis, and bronchitis.
A previous study showed that the flavonoids of L.
pterodonta have anti-inflammatory and anti-apoptotic
effects [5, 6]. Three dicaffeoylquinic acids isolated from L.
pterodonta showed significant inhibitory activity against
herpes simplex virus-1 (HSV-1), herpes simplex virus-2
(HSV-2) and influenza viruses A (IVA) in vitro [7].
To further study the pharmacological mechanism
against influenza virus, the active fr 14 was isolated from
L. pterodonta, and its chemical composition was analysed.
Then, the antiviral spectrum and mechanisms were
demonstrated in this study.Methods
Plant medicine, cells and viruses
L. pterodonta was collected from Yunnan province. The
herbarium specimen was authenticated by Professor
Rongping Zhang and deposited in the College of
Pharmaceutical Sciences, Kunming Medicine University.
Madin-Darby canine kidney (MDCK) and A549 cells
were purchased from the American Tissue Culture
Collection (ATCC). The cells were grown in minimal
essential medium (MEM) with 10% heat-inactivated
foetal calf serum (FCS) supplemented with 1% penicillin
and streptomycin. Oseltamivir carboxylic acid was
purchased from TLC PharmaChem., Inc (Canada).
Influenza virus A/PR/8/34 (H1N1) and influenza virus
A/Aichi/2/68 (H3N2) were purchased from ATCC while
influenza (A/Guangzhou/GIRD/07/09, H1N1) and Flu B
were isolated from routine clinical specimens. Several
strains of avian influenza virus, including A/Duck/
Guangdong/2009 (H6N2), A/Duck/Guangdong/1994
(H7N3) and A/Chicken/Guangdong/1996 (H9N2), were
obtained from in-house repository. The influenza vi-
ruses were propagated in the allantoic cavities of
chicken eggs.Isolation of a sesquiterpene fraction
The sample powder (40 g) was extracted using ultrasonic
wave, adding 5 times methanol and repeating five times
for 30 min. The extract was centrifuged at 2500 g for a
further 10 min. The extracts were combined and
condensed to a proper volume under reduced pressure.
The solution was transferred to the MCI gel column and
eluted with water, aqueous MeOH (10–100%) and
methanol acetone (10–30%) of decreasing polarities to
yield twenty-three fractions. The ultra-high-performance
liquid chromatography hyphenated with mass spectrom-
etry (UHPLC-MS) was used to analyze the fractions bycomparing both accurate mass and fragment patterns. Fr
14 was found to be rich in sesquiterpenes.
UHPLC/QTOF-MS analysis
Samples were analyzed on an Agilent 1290 Infinity
UHPLC system (Santa Clara, CA, USA) equipped with a
binary solvent delivery system and a standard auto-
sampler. The conditions used were: column temperature
30 °C; injection volume 2.0 μl; mobile phase 0.1% aque-
ous solution formic acid (solution A) and acetonitrile
(solution B). The mobile phase was programmed as fol-
lows: 0–8 min, solution B 45–70%; 8–10 min, solution B
70–100%. The mobile phase was pumped at a constant
flow rate of 0.35 ml/min.
Mass spectrometry was performed using an Agilent
6540 ultrahigh definition (UHD) QTOF mass spectrom-
eter (Santa Clara, CA, USA), equipped with a Jet Stream
electrospray ionization (ESI) source. Parameters were as
follows: Capillary voltage 4000 V for positive mode and
3500 V for negative mode, Nebulizer gas pressure 35 psi,
drying gas flow rate 8 L/min, gas temperature 200 °C,
nozzle voltage 300 V, skimmer 65 V, OCT RF V 600 V,
fragmentor 150 V. The collision energy (CE) was set at
10V for MS mode and 10–40 V for auto MS/MS mode.
The mass range recorded in the range of m/z 100–1700.
Cytotoxicity assay
The cytotoxicity of various concentrations of fr 14 to
MDCK cells were determined using an MTT assay. The
cells, which were grown to 80–90% confluence in 96-
well plates, were untreated or treated with the indicated
amounts of drugs and cultured at 37 °C for 2 days. Then,
the cells were treated with 5 mg/ml thiazole blue
tetrazolium bromide in phosphate-buffered saline (PBS)
and incubated for 4 h at 37 °C. The reaction product
was dissolved in DMSO, and the cells were further incu-
bated for 20 min at 37 °C. The absorbance was measured
using a microplate reader at 570 nm [8]. The 50% toxic
concentration (TC50) was calculated by Reed–Muench
analysis [9].
Inhibitory effect of fr 14
The 96-well plates were prepared and cultured with
MDCK cells at 37 °C, 5% CO2 for 24 h. To evaluate the
anti-influenza activity of the fraction, cells were washed
with PBS and infected with 100 TCID50 (median tissue
culture infective dose) of influenza virus (PR8 strain) at
37 °C for 2 h. Then, the medium was removed, and the
indicated fractions were added at different concentra-
tions with a two-fold dilution in serum-free MEM sup-
plemented with 2 μg/ml TPCK-trypsin. After incubation
for 48 h at 34 °C, the cytopathogenic efficiency (CPE)
caused by the influenza virus was measured microscop-
ically. The concentration required for 50% inhibition of
Table 1 The chemical data of fr 14
Number. peak Formula Compound name Reference
1 C15H20O3 Tessaric acid or pterodonoic acid [26, 27]
2 C15H24O3 Isomer of ilicic acid [12]
3 C15H20O3 Tessaric acid or pterodonoic acid [26, 27]






5 C15H24O3 Ilicic acid [12]
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Muench method [10].Time of addition assay
MDCK cells growing in 24-well plates were then adsorbed
with virus (A/PR/8/34, 0.01 MOI) for 2 h at 4 °C. Then,
the cells were washed with cold PBS twice to remove the
unbound virus. Next, MEM was added to the cells, and
incubation was performed in a CO2 incubator at 37 °C. Fr
14 was added 2 h prior to the infection (-2 h) or at the
same time with the virus infection (0 h), and at indicated
time points post-infection (2 h, 4 h, 6 h, 8 h). Following
incubation for 10 h, the supernatants were collected and
infectious titres were determined by CPE assay [10].Detection of cytokines and chemokines by qRT-PCR
A549 cells growing in 96-well plates at 37 °C, 5%
CO2 were prepared and then infected with influenza
virus (A/PR/8/34, 0.1 MOI) for 2 h. The inoculums
were removed, and the cells were treated with various
concentrations of fr 14. The cells were collected at 24 h
post-infection, and the total RNA was extracted using the
TRIZOL reagent assay (Invitrogen) to detect the expres-
sion of TNF-α, IL-8, IL-6, MCP-1, IP-10, and RANTES by
quantitative RT-PCR using the ABI 7500 Real-time PCR
System [11].Fig. 1 UHPLC-QTOF MS total ion chromatogram of the sesquiterpene fractDetection of cytokines and chemokines by bio-plex assay
A549 cells were grown in 6-well plates and then washed
with PBS twice. The virus (A/PR/8/34, 0.01 MOI) was
incubated with the cells for 2 h. Then, fr 14 was added
at different concentrations. The supernatants were col-
lected after 24 h and centrifuged at 13000 rpm at 4 °C to
remove the cell debris. Cytokines were detected using
the bio-plex liquid phase chips kit with the bio-plex 200
system [11].
Western blotting assay
A549 cells were prepared and washed with PBS, then
incubated with virus A/PR/8/34 (MOI = 0.1) diluted in
PBS for 30 min at 37 °C. Then, the inoculums were
discarded, and the cells were incubated with MEM in
the absence and presence of different concentrations of
fr 14 for 24 h at 37 °C. Cell lysis and western blots were
performed as previously described [10].
Results
Characterization of fr 14
The chemical data of the proposed compounds are
shown in Table 1. Here we take peak 5 in Fig. 1 as an
example to illustrate its identification process. Precursor
ions of peak 5 were obtained in positive mode and
negative mode, offering molecular fomular of C15H24O3.
Further more, MS/MS fragments were observed select-
ing m/z 275.16 ([M +Na]+) as precursor ion. Compound
of peak 5 was illustrated as shown in Fig. 2, and it was
identified as compound of ilicic acid by comparing
accurate mass and molecular formula with data reported
in the literature [12]. Besides, precursor ions and MS/
MS fragments from peak 2 were found almost the same
as those of peak 5, which indicated difference is the
position of hydroxyl group between compounds of peak
2 and peak 5. Therefore, compound of peak 2 was
identified as an isomer of ilicic acid. By using the similar
procedure, other compounds could be identified in this
experiment [13].ion obtained from L. pterodonta
Fig. 2 MS/MS spectrum illustration for compound of peak 5 in positive mode
Table 2 The antiviral spectrum of fr 14
Virus strains fr14 (μg/ml) Oseltamivir (μg/ml)
TC50 IC50 SI TC50 IC50 SI
A/PR/8/34 (H1N1) >200 79.4 >2.52 >1000 0.05 >1000
A/Guangzhou/GIRD07/09 (H1N1) >200 43.5 >4.59 >1000 0.11 >1000
A/Aichi/2/68 (H3N2) >200 75 >2.67 >1000 0.06 >1000
Flu B >200 >100 <2 >1000 6.31 >150
A/Duck/Guangdong/2009 (H6N2) >200 >150 <1.33 >1000 NTa NTa
A/Duck/Guangdong/1994 (H7N3) >200 >150 <1.33 >1000 NTa NTa
A/Chicken/Guangdong/1996 (H9N2) >200 >150 <1.33 >1000 NTa NTa
aNT: not test
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Fig. 3 The time-of-addition assay. MDCK cells were prepared in a 24-
well plate and then adsorbed with virus (A/PR/8/34, 0.01 MOI) for 2 h
at 4 °C. Then, the cells were washed and MEM was added to the cells.
Fr 14 was added 2 h prior to the infection (-2 h) or at the same time as
the virus infection (0 h) and at the indicated time points post-infection
(2 h, 4 h, 6 h, 8 h). Following incubation for 10 h, the supernatants were
collected, and infectious titres were determined by CPE assay
Fig. 4 Inhibition of inflammatory cytokines in A549 cells post influenza viru
37 °C, 5% CO2 were prepared and then infected with influenza virus (A/PR/
were treated with various concentrations of fr 14. The cells were collected
IL-8, MIP-1α, IFN- α, and MIG by RT-PCR
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The antiviral spectrum determined by CPE assay demon-
strated that fr 14 can inhibit different influenza strains,
namely influenza viruses A/PR/8/34, A/Guangzhou/
GIRD07/09 (H1N1) and A/Aichi/2/68 (H3N2), but failed
to inhibit avian influenza virus, such as H6N2, H7N3, and
H9N2 (Table 2).The inhibition stage of influenza virus replication by fr 14
A time-of-addition experiment was performed to confirm
the stage of influenza virus replication influenced by fr 14.
Fr 14 was added at different time points and showed po-
tent antiviral activity at 0–6 h, which was during the early
stage of virus replication (Fig. 3). Therefore, the entry and
absorption step, or endosomal, of nucleic acid release of
the influenza virus might have been inhibited by fr 14.s infection at the mRNA level. A549 cells growing in a 96-well plate at
8/34, 0.1 MOI) for 2 h. The inoculums were removed, and the cells
at 24 h post-infection to determine the expression of IP-10, TNF-α,
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influenza virus infection in mRNA and protein levels
Inflammatory cytokine expression deregulation is a
risk factor for the healthy population, and excessive
secretion will cause tissue damage. Therefore, the
effects of fr 14 on inducing cytokine productions
were determined. The results showed that the mRNAs
of IP-10, TNF-α, IL-8, MIP-1α, IFN- α, and MIG
were significantly reduced in fr 14-treated cells at 24 h
post infection (Fig. 4).
The inflammatory cytokines were further verified at
protein levels. The bio-plex analysis results showed that
higher levels of TNF-α, IL-8, IL-6, MCP-1, IP-10, and
RANTES expression were detected in the influenza virus
infection group but that the levels in the drug-treated
group of different concentrations (150, 100, 50 μg/ml)
decreased (Figs. 5 and 6).Fig. 5 Inhibition of inflammatory cytokines in A549 cells post influenza
6-well plate and then washed with PBS twice. The virus (A/PR/8/34, 0.01 MO
concentrations. The supernatants were collected after 24 h, and the cytokines
200 systemInhibition of influenza virus-induced signalling pathway
by fr14
Influenza virus infections cause NF-κB, p38, and ERK
activation. The results in Fig. 5 showed that fr 14 can
inhibit the protein phosphorylation of p65 and p38, but
had no effect on the ERK pathway. NF-κB plays an
important role in the regulation of COX-2 and iNOS
expression; therefore, COX-2 was also inhibited.
Discussion
The influenza virus causes respiratory disease, including
headache, cough, sore throat, rhinorrhoea, and severe
pneumonia, and these symptoms are especially prevalent
in newly emerged viruses, such as recombinant avian
influenza virus [14, 15]. However, anti-influenza drugs
are limited due to resistance. Therefore, it is necessary
to explore alternative drugs.virus infection at the protein level. A549 cells were grown in a
I) was incubated with the cells for 2 h, and fr 14 was added at different
were detected using the bio-plex liquid phase chips kit with the bio-plex
Fig. 6 Inhibition of influenza virus-induced signalling pathway by fr14.
A549 cells were washed with PBS and subsequently incubated with
virus A/PR/8/34 (MOI = 0.1) diluted in PBS for 30 min at 37 °C. Then,
the inoculums were aspirated, and the cells were incubated with
MEM in the absence and presence of different concentrations
(150, 100, 50 μg/ml) of fr 14 for 24 h at 37 °C. Cell lysis and
western blots were performed
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for a long time clinically. Various extracts, fractions or
compounds isolated from TCM have demonstrated
antiviral activity with different mechanisms [16].
In our research, fr 14 was isolated from L. pterodonta,
and the antiviral mechanisms of fr 14 were detected in
our present study. First, the specific steps of influenza
virus replication inhibited by fr 14 were tested. The
results showed that the fraction can inhibit virus replica-
tion when added at 0–6 h, which indicates that the entry
and absorption step, or endosomal, nucleic acid release,
may be inhibited. Another possibility is related to the
host immune regulation.
Influenza viruses are parasitic and need the host’s
cellular function to achieve their life cycle. The previous
study showed that 219 of the 295 factors were required
for efficient influenza virus growth based on a genome-
wide RNAi screening experiment [17].
Influenza virus infection can induce the host signalling
pathways, such as ERK/MAPK, p38/MAPK, and NF-κB.
ERK and p38 belong to the mitogen-activated protein
kinase (MAPK) family, which is involved in cell growth,
apoptosis and the immune response [18]. Raf/MEK/ERK
is essential for influenza virus replication, and the ERK
inhibitor U0126 can inhibit the nuclear export of the
viral RNPs in the virus replication cycle [19].The nuclear factor kappa B (NF-κB) families are critical
transcription factors regulating inflammation and apop-
tosis. The influenza virus proteins HA and NA, or viral
RNA accumulation, can activate the NF-κB signalling
pathway, which is the hallmark of virus infection. It was re-
ported that the NF-κB signalling pathway can be exploited
by the virus to block apoptosis and prolong the survival of
the host cell and increase viral progeny production. NF-κB
is also involved in the inflammatory response, inducing the
transcription of proinflammatory cytokines, such as TNF-
α, IL-6, and IL-8, and the expression of enzymes, such as
inducible cyclooxygenase [20, 21]. P38 is also related to the
innate immune response, controlling the expression of
cytokines such as RANTES, IL-8 and TNF-α [22], and
research has demonstrated that p38/MAPK may act as an
upstream activator of the NF-κB signalling pathway [23].
Our results indicated that fr 14 inhibited the protein p65/
NF-κB and p38/MAPK phosphorylation at concentrations
of 50, 100, and 150 μg/ml but did not affect ERK/MAPK.
Based on previous data [23], the mechanisms of fr 14 may
be a cascade process that inhibited p38/MAPK, inhibited
NF-κB, and further inhibited COX-2.
Cytokines and chemokines play an important role in
influenza virus infection, especially highly pathogenic
influenza viruses. TNF-α, IFN-α, and IL-1 are expressed
in the early cytokine cascade, followed by IL-6 and
chemokines, such as IL-8, MCP-1, MIP-1, IP-10, and
MIG [24]. Previous findings found that IL-6 may be a
potential disease severity biomarker for severe pandemic
H1N1 Influenza A infection [25]. Chemokines IP-10 and
RANTES can act to damage host tissue by recruiting
monocytes, macrophages, DCs, and T cells that enhance
inflammatory processes [24].
Our results demonstrated that TNF-α, IL-8, IP-10,
MIG, MIP-1α, and IFN-α were decreased at the mRNA
level after treatment by fr 14 (50, 150 μg/ml). The bio-
plex analysis results demonstrated that the drug-treated
group of different concentrations (150, 100, 50 μg/ml)
can inhibit TNF-α, IL-8, IP-10, IL-6, MCP-1, and
RANTES expression at the protein level. The inhibition
of increased cytokine and chemokine expression may
also be related to the p38 and NF-κB pathways.Conclusion
In this study, active fractions were isolated from L. ptero-
donta. Fr 14 had a wide spectrum of anti-influenza virus
activity. The pharmacological mechanisms showed that fr
14 acts on the early stages of virus replication (0–6 h). Fr
14 inhibited p38/MAPK and then inhibited NF-κB and
COX-2. Fr 14 also prevented an increase in cytokines and
chemokines expression. L. pterodonta can be used to
develop an innovative antiviral drug, and further studies
will be performed to illustrate the detailed mechanisms.
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